Evidence map›Paper›PMID 32647027›Full record

ArticleAnnals of the rheumatic diseases2021

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.

Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 8 pooled it
1.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 8 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.The New England journal of medicine · 2020
    Trial
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Nicola PotereDepartment of Medical, Oral and Biotechnological Sciences, "G D'Annunzio" University, Chieti, Italy.
Marcello Di NisioDepartment of Medicine and Ageing Sciences, "G' D'Annunzio" University, Chieti-Pescara, Italy.
Donatella CibelliInfectious Diseases Unit, Pescara General Hospital, Pescara, Italy.
Rosa ScurtiGeriatric Medicine Unit, Pescara General Hospital, Pescara, Italy.
Antonella FrattariIntensive Care Unit, Pescara General Hospital, Pescara, Italy.
Ettore PorrecaDepartment of Medical, Oral and Biotechnological Sciences, "G D'Annunzio" University, Chieti, Italy.
Antonio AbbateVCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.
Giustino ParrutiInfectious Diseases Unit, Pescara General Hospital, Pescara, Italy parrutig@gmail.com.ORCID 0000-0003-3483-8170
Azienda USL di Pescara · ITUniversity of Chieti-Pescara · ITVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentAdultAntibodies, Monoclonal, HumanizedCase-Control StudiesCOVID-19FemaleHumansInflammationMaleMiddle AgedReceptors, Interleukin-6Retrospective StudiesSARS-CoV-2Treatment OutcomeAntibodies, Monoclonal, HumanizedIL6R protein, humanReceptors, Interleukin-6tocilizumabbiological therapycytokinesimmune system diseasesinflammation

Identifiers

PMID32647027
OpenAlexW3042214572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.